{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T08:20:23Z","timestamp":1778574023922,"version":"3.51.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,2]]},"DOI":"10.7759\/cureus.106336","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T22:10:29Z","timestamp":1775167829000},"source":"Crossref","is-referenced-by-count":1,"title":["Correlation of MRI-Derived Apparent Diffusion Coefficient (ADC) Values With Gleason Scores in Prostate Cancer and Quantitative Prostate MRI Reading"],"prefix":"10.7759","author":[{"given":"Victoria Y","family":"Bird","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krystina","family":"Masihy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Varela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Busch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.811044","article-title":"Prostate cancer incidence and mortality: global status and temporal trends in 89 countries from 2000 to 2019","volume":"10","author":"Wang L","year":"2022","unstructured":"Wang L, Lu B, He M, Wang Y, Wang Z, Du L. Prostate cancer incidence and mortality: global status and temporal trends in 89 countries from 2000 to 2019. Front Public Health. 2022, 10:10.3389\/fpubh.2022.811044","journal-title":"Front Public Health"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-5347(17)59889-4","article-title":"Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging","volume":"111","author":"Gleason DF","year":"1974","unstructured":"Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol. 1974, 111:58-64. 10.1016\/s0022-5347(17)59889-4","journal-title":"J Urol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/pas.0000000000000530","article-title":"The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system","volume":"40","author":"Epstein JI","year":"2016","unstructured":"Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA. The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol. 2016, 40:244-52. 10.1097\/pas.0000000000000530","journal-title":"Am J Surg Pathol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-157-2-201207170-00459","article-title":"Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement","volume":"157","author":"Moyer VA","year":"2012","unstructured":"Moyer VA. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012, 157:120-34. 10.7326\/0003-4819-157-2-201207170-00459","journal-title":"Ann Intern Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.08.052","article-title":"PI-RADS Prostate Imaging-Reporting and Data System: 2015, version 2","volume":"69","author":"Weinreb JC","year":"2016","unstructured":"Weinreb JC, Barentsz JO, Choyke PL, et al.. PI-RADS Prostate Imaging-Reporting and Data System: 2015, version 2. Eur Urol. 2016, 69:16-40. 10.1016\/j.eururo.2015.08.052","journal-title":"Eur Urol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.02.033","article-title":"Prostate Imaging Reporting and Data System version 2.1: 2019 update of Prostate Imaging Reporting and Data System version 2","volume":"76","author":"Turkbey B","year":"2019","unstructured":"Turkbey B, Rosenkrantz AB, Haider MA, et al.. Prostate Imaging Reporting and Data System version 2.1: 2019 update of Prostate Imaging Reporting and Data System version 2. Eur Urol. 2019, 76:340-51. 10.1016\/j.eururo.2019.02.033","journal-title":"Eur Urol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.12.10173","article-title":"Comparison of interreader reproducibility of the Prostate Imaging Reporting and Data System and Likert scales for evaluation of multiparametric prostate MRI","volume":"201","author":"Rosenkrantz AB","year":"2013","unstructured":"Rosenkrantz AB, Lim RP, Haghighi M, Somberg MB, Babb JS, Taneja SS. Comparison of interreader reproducibility of the Prostate Imaging Reporting and Data System and Likert scales for evaluation of multiparametric prostate MRI. AJR Am J Roentgenol. 2013, 201:612-18. 10.2214\/AJR.12.10173","journal-title":"AJR Am J Roentgenol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0079008","article-title":"The correlation between apparent diffusion coefficient and tumor cellularity in patients: a meta-analysis","volume":"8","author":"Chen L","year":"2013","unstructured":"Chen L, Liu M, Bao J, et al.. The correlation between apparent diffusion coefficient and tumor cellularity in patients: a meta-analysis. PLoS One. 2013, 8:10.1371\/journal.pone.0079008","journal-title":"PLoS One"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm E","year":"2008","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008, 61:344-9. 10.1016\/j.jclinepi.2007.11.008","journal-title":"J Clin Epidemiol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20180091","article-title":"Utility of quantitative apparent diffusion coefficient measurements and normalized apparent diffusion coefficient ratios in the diagnosis of clinically significant peripheral zone prostate cancer","volume":"91","author":"Nguyen TB","year":"2018","unstructured":"Nguyen TB, Ushinsky A, Yang A, et al.. Utility of quantitative apparent diffusion coefficient measurements and normalized apparent diffusion coefficient ratios in the diagnosis of clinically significant peripheral zone prostate cancer. Br J Radiol. 2018, 91:10.1259\/bjr.20180091","journal-title":"Br J Radiol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-06942-x","article-title":"Discrimination between clinical significant and insignificant prostate cancer with apparent diffusion coefficient - a systematic review and meta analysis","volume":"20","author":"Meyer HJ","year":"2020","unstructured":"Meyer HJ, Wienke A, Surov A. Discrimination between clinical significant and insignificant prostate cancer with apparent diffusion coefficient - a systematic review and meta analysis. BMC Cancer. 2020, 20:482. 10.1186\/s12885-020-06942-x","journal-title":"BMC Cancer"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2010.0012","article-title":"NCCN clinical practice guidelines in oncology: prostate cancer","volume":"8","author":"Mohler J","year":"2010","unstructured":"Mohler J, Bahnson RR, Boston B, et al.. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw. 2010, 8:162-200. 10.6004\/jnccn.2010.0012","journal-title":"J Natl Compr Canc Netw"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.03.033","article-title":"A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy","volume":"64","author":"Zumsteg ZS","year":"2013","unstructured":"Zumsteg ZS, Spratt DE, Pei I, Zhang Z, Yamada Y, Kollmeier M, Zelefsky MJ. A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy. Eur Urol. 2013, 64:895-902. 10.1016\/j.eururo.2013.03.033","journal-title":"Eur Urol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0044","article-title":"Prostate MRI: evaluating tumor volume and apparent diffusion coefficient as surrogate biomarkers for predicting tumor Gleason score","volume":"20","author":"Donati OF","year":"2014","unstructured":"Donati OF, Afaq A, Vargas HA, et al.. Prostate MRI: evaluating tumor volume and apparent diffusion coefficient as surrogate biomarkers for predicting tumor Gleason score. Clin Cancer Res. 2014, 20:3705-11. 10.1158\/1078-0432.CCR-14-0044","journal-title":"Clin Cancer Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.11091409","article-title":"Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer","volume":"259","author":"Hambrock T","year":"2011","unstructured":"Hambrock T, Somford DM, Huisman HJ, et al.. Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer. Radiology. 2011, 259:453-61. 10.1148\/radiol.11091409","journal-title":"Radiology"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.14.13146","article-title":"Apparent diffusion coefficient value and ratio as noninvasive potential biomarkers to predict prostate cancer grading: comparison with prostate biopsy and radical prostatectomy specimen","volume":"204","author":"De Cobelli F","year":"2015","unstructured":"De Cobelli F, Ravelli S, Esposito A, Giganti F, Gallina A, Montorsi F, Del Maschio A. Apparent diffusion coefficient value and ratio as noninvasive potential biomarkers to predict prostate cancer grading: comparison with prostate biopsy and radical prostatectomy specimen. AJR Am J Roentgenol. 2015, 204:550-7. 10.2214\/AJR.14.13146","journal-title":"AJR Am J Roentgenol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15215183","article-title":"Quantitative evaluation of apparent diffusion coefficient values, ISUP grades and prostate-specific antigen density values of potentially malignant PI-RADS lesions","volume":"15","author":"Spadarotto N","year":"2023","unstructured":"Spadarotto N, Sauck A, Hainc N, Keller I, John H, Hohmann J. Quantitative evaluation of apparent diffusion coefficient values, ISUP grades and prostate-specific antigen density values of potentially malignant PI-RADS lesions. Cancers (Basel). 2023, 15:10.3390\/cancers15215183","journal-title":"Cancers (Basel)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/pros.24658","article-title":"Based on PI-RADS v2.1 combining PHI and ADC values to guide prostate biopsy in patients with PSA 4-20\u2009ng\/mL","volume":"84","author":"Huang H","year":"2024","unstructured":"Huang H, Liu Z, Ma Y, et al.. Based on PI-RADS v2.1 combining PHI and ADC values to guide prostate biopsy in patients with PSA 4-20\u2009ng\/mL. Prostate. 2024, 84:376-88. 10.1002\/pros.24658","journal-title":"Prostate"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-019-02827-2","article-title":"Effects of the addition of quantitative apparent diffusion coefficient data on the diagnostic performance of the PI-RADS v2 scoring system to detect clinically significant prostate cancer","volume":"38","author":"Moraes MO","year":"2020","unstructured":"Moraes MO, Roman DH, Copetti J, et al.. Effects of the addition of quantitative apparent diffusion coefficient data on the diagnostic performance of the PI-RADS v2 scoring system to detect clinically significant prostate cancer. World J Urol. 2020, 38:981-91. 10.1007\/s00345-019-02827-2","journal-title":"World J Urol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1097\/RCT.0000000000001560","article-title":"Comparison of the utility of PI-RADS 2.1, ADC values, and combined use of both, for the diagnosis of transition zone prostate cancers","volume":"48","author":"Liu X","year":"2024","unstructured":"Liu X, Xiong Q, Zeng W, Yang R, Wen Y, Li X. Comparison of the utility of PI-RADS 2.1, ADC values, and combined use of both, for the diagnosis of transition zone prostate cancers. J Comput Assist Tomogr. 2024, 48:206-11. 10.1097\/RCT.0000000000001560","journal-title":"J Comput Assist Tomogr"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2024.06.014","article-title":"Clinical-imaging metrics for the diagnosis of prostate cancer in PI-RADS 3 lesions","volume":"42","author":"Kang Z","year":"2024","unstructured":"Kang Z, Margolis DJ, Tian Y, Li Q, Wang S, Wang L. Clinical-imaging metrics for the diagnosis of prostate cancer in PI-RADS 3 lesions. Urol Oncol. 2024, 42:1-10. 10.1016\/j.urolonc.2024.06.014","journal-title":"Urol Oncol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.17.18702","article-title":"Can apparent diffusion coefficient values assist PI-RADS version 2 DWI scoring? A correlation study using the PI-RADSv2 and International Society of Urological Pathology Systems","volume":"211","author":"Gaur S","year":"2018","unstructured":"Gaur S, Harmon S, Rosenblum L, et al.. Can apparent diffusion coefficient values assist PI-RADS version 2 DWI scoring? A correlation study using the PI-RADSv2 and International Society of Urological Pathology Systems. AJR Am J Roentgenol. 2018, 211:33-41. 10.2214\/AJR.17.18702","journal-title":"AJR Am J Roentgenol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.13130973","article-title":"Prostate cancer aggressiveness: assessment with whole-lesion histogram analysis of the apparent diffusion coefficient","volume":"271","author":"Donati OF","year":"2014","unstructured":"Donati OF, Mazaheri Y, Afaq A, et al.. Prostate cancer aggressiveness: assessment with whole-lesion histogram analysis of the apparent diffusion coefficient. Radiology. 2014, 271:143-52. 10.1148\/radiol.13130973","journal-title":"Radiology"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-023-02324-y","article-title":"Clinical value of minimum apparent diffusion coefficient for prediction of clinically significant prostate cancer in the transition zone","volume":"28","author":"Ono A","year":"2023","unstructured":"Ono A, Hashimoto T, Shishido T, et al.. Clinical value of minimum apparent diffusion coefficient for prediction of clinically significant prostate cancer in the transition zone. Int J Clin Oncol. 2023, 28:716-23. 10.1007\/s10147-023-02324-y","journal-title":"Int J Clin Oncol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000003269","article-title":"The role of apparent diffusion coefficient values in diagnosing prostate cancer for patients with equivocal PI-RADS 3 lesions: a multicenter retrospective study","volume":"111","author":"Wang C","year":"2025","unstructured":"Wang C, Dong Q, Yuan L, et al.. The role of apparent diffusion coefficient values in diagnosing prostate cancer for patients with equivocal PI-RADS 3 lesions: a multicenter retrospective study. Int J Surg. 2025, 111:9038-48. 10.1097\/JS9.0000000000003269","journal-title":"Int J Surg"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14207150","article-title":"Predictive value of quantitative ADC, SUVmax, and the SUVmax\/ADC ratio for biological behavior and prognosis in high-risk prostate cancer","volume":"14","author":"Ata\u015f AE","year":"2025","unstructured":"Ata\u015f AE, Kerimo\u011flu \u00dc, \u0130lhan Z, \u00dcn\u00fcvar \u015e, \u015eahin \u00d6, Ayd\u0131n Z, Esen HH. Predictive value of quantitative ADC, SUVmax, and the SUVmax\/ADC ratio for biological behavior and prognosis in high-risk prostate cancer. J Clin Med. 2025, 14:10.3390\/jcm14207150","journal-title":"J Clin Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2022.06.011","article-title":"The prognostic value of mean apparent diffusion coefficient measured with diffusion-weighted magnetic resonance image in patients with prostate cancer treated with definitive radiotherapy","volume":"173","author":"Onal C","year":"2022","unstructured":"Onal C, Erbay G, Guler OC, Oymak E. The prognostic value of mean apparent diffusion coefficient measured with diffusion-weighted magnetic resonance image in patients with prostate cancer treated with definitive radiotherapy. Radiother Oncol. 2022, 173:285-91. 10.1016\/j.radonc.2022.06.011","journal-title":"Radiother Oncol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000002254","article-title":"68GA-prostate-specific membrane antigen positron emission tomography maximum standardized uptake value as a predictor of Gleason pattern 4 and pathological upgrading in intermediate-risk prostate cancer","volume":"207","author":"Xue AL","year":"2022","unstructured":"Xue AL, Kalapara AA, Ballok ZE, et al.. 68GA-prostate-specific membrane antigen positron emission tomography maximum standardized uptake value as a predictor of Gleason pattern 4 and pathological upgrading in intermediate-risk prostate cancer. J Urol. 2022, 207:341-9. 10.1097\/JU.0000000000002254","journal-title":"J Urol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2025.111090","article-title":"Predictive utility of post-treatment tumor apparent diffusion coefficient in high-risk prostate cancer undergoing definitive radiotherapy: a long-term outcome analysis","volume":"211","author":"Onal C","year":"2025","unstructured":"Onal C, Erbay G, Guler OC, Demirhan B, Elmali A, Yavuz M. Predictive utility of post-treatment tumor apparent diffusion coefficient in high-risk prostate cancer undergoing definitive radiotherapy: a long-term outcome analysis. Radiother Oncol. 2025, 211:10.1016\/j.radonc.2025.111090","journal-title":"Radiother Oncol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.crad.2023.12.022","article-title":"Early change in apparent diffusion coefficient as a predictor of response to neoadjuvant androgen deprivation and external beam radiation therapy for intermediate- to high-risk prostate cancer","volume":"79","author":"Franco FB","year":"2024","unstructured":"Franco FB, Leeman JE, Fedorov A, Vangel M, Fennessy FM. Early change in apparent diffusion coefficient as a predictor of response to neoadjuvant androgen deprivation and external beam radiation therapy for intermediate- to high-risk prostate cancer. Clin Radiol. 2024, 79:607-15. 10.1016\/j.crad.2023.12.022","journal-title":"Clin Radiol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/458400-correlation-of-mri-derived-apparent-diffusion-coefficient-adc-values-with-gleason-scores-in-prostate-cancer-and-quantitative-prostate-mri-reading","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T22:10:29Z","timestamp":1775167829000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/458400-correlation-of-mri-derived-apparent-diffusion-coefficient-adc-values-with-gleason-scores-in-prostate-cancer-and-quantitative-prostate-mri-reading"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.106336","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,2]]}}}